PSI reaches into Austria; Almac inks a $365M Roche deal;

> Swiss CRO PSI has opened a new outpost in Vienna, part of a sweeping effort to expand across Europe. More

> Almac's drug discovery operation has inked a deal with Roche's ($RHHBY) Genentech, out-licensing a cancer program for $14.5 million up front and as much as $349 million in milestones. News

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.